Clicky

Jazz Pharmaceuticals plc(JAZZ)

Description: Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland.


Keywords: Medicine Biotechnology Cancer Biopharmaceutical Clinical Medicine Pharmaceutical Products Drugs Pain Imaging Antibiotics Prostate Cancer Lymphoma Monoclonal Antibody Bone Transplantation IBD 50 Schizophrenia Chronic Pain Suspension Pharmacokinetics Oral Hygiene Acute Lymphoblastic Leukemia Meningitis Movement Disorders Organ Transplantation Host Disease Narcolepsy Oral Mucositis Pegylation Obsessive Compulsive Disorder Organ Transplant Mucositis Asparaginase Caphosol Cataplexy Idiopathic Parkinson's Disease Luvox Cr Panic Disorder

Home Page: www.jazzpharma.com

JAZZ Technical Analysis

Waterloo Exchange
Dublin, 4
Ireland
Phone: 353 1 634 7800


Officers

Name Title
Mr. Bruce C. Cozadd Co-Founder, Chairman & CEO
Mr. Daniel N. Swisher Jr. Pres & COO
Ms. Renee D. Gala Exec. VP & CFO
Dr. Robert Iannone M.D. Exec. VP and Global Head of R&D
Ms. Patricia Carr Sr. VP & Chief Accounting Officer
Dr. Finbar Larkin Ph.D. Sr. VP of Technical Operations
Ms. Andrea N. Flynn Ph.D. VP & Head of Investor Relations
Ms. Neena M. Patil J.D. Exec. VP & Chief Legal Officer
Dr. George Christopher Eliades Ph.D. Sr. VP of Corp. Devel. & Chief Transformation Officer
Ms. Heidi Manna Sr. VP & Chief HR Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 9.1075
Trailing PE: 0
Price-to-Book MRQ: 3.6126
Price-to-Sales TTM: 2.6873
IPO Date: 2007-06-01
Fiscal Year End: December
Full Time Employees: 3200
Back to stocks